July 28, 2007 |
Some women can regain access to a constipation drug withdrawn after being linked to a higher risk of heart attack and stroke, federal officials said. Women younger than 55 with irritable bowel syndrome and chronic constipation who meet specific guidelines will be allowed access to Zelnorm, the Food and Drug Administration said. The drug remains off the market for general use.
August 25, 2000 |
The government is sending to women's homes a major warning about a popular new treatment for irritable bowel syndrome: The drug Lotronex sometimes causes severe intestinal side effects--some requiring surgery--so stop taking it at the earliest sign of a problem. Hoping to help women safeguard themselves, the Food and Drug Administration announced it has ordered Glaxo Wellcome Inc. to attach to every Lotronex bottle a pamphlet explaining the risk.
August 31, 2012 |
The Food and Drug Administration on Thursday approved a new drug, Linzess, to treat irritable bowel syndrome with constipation. The drug, known generically as linaclotide, speeds up bowel movements and reduces pain in many patients with the disorder. It is the second product on the market aimed at the population, following Amitiza (lubiprostone), which was approved in January 2006 but may have more side effects than Linzess. An estimated 15.3 million Americans suffer from irritable bowel syndrome with constipation, according to the National Institutes of Health, and about 63 million suffer from constipation.
November 29, 2013 |
Ever wonder why some people, even under adverse circumstances, set goals and achieve them effortlessly? Some of them, undoubtedly, are hard-wired to succeed. They just set themselves in a direction and their mind handles the rest. But that ability is atypical; most of us, at one time or another, are daunted by illness or other mental or physical challenges. That's where hypnosis can come in. Experts in a variety of fields say that patients become highly focused and open to suggestions when they are in a trance-like state.
December 8, 2003 |
Peppermint is approved in Europe for treating colds, coughs, dyspepsia and liver conditions. In this country, the hardy perennial is often found in herbal remedies for stomach ailments and is sold as a dietary supplement. The herb's main ingredient is menthol, but it also contains flavonoids such as limonene. * Uses: Some herbalists recommend the herb or its oil for colds, coughs and headaches. It's also sometimes used to ease upset stomachs, irritable bowel syndrome and indigestion.
June 1, 2007
Re "You know what makes me sick?" Opinion, May 27 As a practicing gastroenterologist and a board member of the Celiac Disease Foundation, I find it unfortunate that Heather Abel accuses physicians of pushing pills after being bought off by drug companies. The failure to diagnose celiac disease is because of symptoms (if any) that are typically subtle and nonspecific, not because of a conspiracy between physicians and drug companies. Abel says her irritable bowel syndrome was treated with Celebrex, which caused ulcers.
December 23, 2002 |
Hypnosis has been so effective in treating irritable bowel syndrome that British researchers recently tested its usefulness for chronic indigestion. More than 100 people at the Wythenshawe Hospital in Manchester, England, were assigned to receive 12 30-minute sessions of either hypnotherapy, supportive therapy and a placebo medication, or medication (rantidine twice a day) over 16 weeks.
November 12, 2000
Re "FDA Minimized Issue of Lotronex's Safety," Nov. 2: It is untrue that Glaxo Wellcome and the FDA have not taken seriously reports of adverse events among women who have taken Lotronex. Both Glaxo Wellcome and the FDA apply the world's highest standards in our efforts to make innovative medicines available. We both have independently scrutinized the benefits and risks and have concluded that, in appropriate patients, Lotronex has a demonstrated benefit in the treatment of diarrhea-predominant irritable bowel syndrome, which can be severely incapacitating.
August 20, 2001 |
Novartis, Europe's third-biggest drug maker, needs to win U.S. approval for the experimental medicine Zometa to start turning around a 18% drop in shares this year, analysts and investors said. The Food and Drug Administration may rule today on the drug, designed to treat a life-threatening condition in which too much calcium enters the bloodstream. The U.S. agency has been reviewing additional data after last year deeming Zometa "approvable."
April 24, 2002 |
Government advisors heeded patients' pleas Tuesday that a drug for irritable bowel syndrome should be cleared for sale again--but with stringent restrictions to try to mitigate side effects that have hospitalized more than 160 people and killed seven.